2-羰基丙酸芳甲酰腙二对甲基苄基锡配合物的合成、晶体结构及生物活性

在含水甲苯中,对甲基氯苄与锡粉反应合成了二对甲基苄基二氯化锡,将其分别与2-羰基丙酸苯甲酰腙及2-羰基丙酸水杨酰腙反应,合成了2个取代苄基锡配合物(1、2),通过元素分析、IR、1H NMR、13C NMR、X射线单晶衍射以及热重分析等表征了配合物结构。测试了配合物对癌细胞MCF-7、Hep G2、NCI-H460以及正常人体肝细胞HL-7702的体外抑制活性;在Tris-HCl缓冲溶液中,以EB作为荧光探针,用荧光光谱法初步研究了配合物与小牛胸腺DNA的相互作用。结果表明:配合物1、2对3种癌细胞都有明显的抑制作用,配合物2对HL-7702的细胞毒性小于1;配合物1与小牛胸腺DNA作用是插入结合与静电结合共同作用所致,配合物2与小牛胸腺DNA作用是插入结合作用所致。     

2-羰基-3-苯基丙酸芳甲酰腙二(2,4-二氯苄基)锡配合物的合成、晶体结构及生物活性

二(2,4-二氯苄基)二氯化锡分别与2-羰基-3-苯基丙酸苯甲酰腙及2-羰基-3-苯基丙酸水杨酰腙反应,合成了2个取代苄基锡配合物(C1、C2),通过元素分析、IR、1H NMR、13C NMR、119Sn NMR、X射线单晶衍射以及热重分析等表征了配合物结构。测试了配合物对癌细胞Hela、MCF7、Hep G2、Colo205、NCI-H460以及正常人体胚肾细胞HEK293、正常人体肝细胞HL7702的体外抑制活性;在Tris-HCl缓冲溶液中,以EB做为荧光探针,用荧光光谱法初步研究了配合物与小牛胸腺DNA的相互作用。结果表明:配合物C1、C2对5种癌细胞都有明显的抑制作用,配合物C2对HEK293、HL7702的细胞毒性远小于C1;配合物C1与小牛胸腺DNA作用是插入结合与静电结合共同作用所致,配合物C2与小牛胸腺DNA作用是插入结合作用所致。     

N-(2-丙酸)-芳甲酰腙二对甲基苄基锡配合物的合成、晶体结构及生物活性

二对甲基苄基二氯化锡分别与N-(2-丙酸)-对硝基苯甲酰腙及N-(2-丙酸)-对叔丁基苯甲酰腙反应,合成了2个取代二苄基锡配合物(C1、C2),通过元素分析、IR、UV-Vis、1H NMR、13C NMR、119Sn NMR、X射线单晶衍射以及热重分析等表征了配合物结构。测试了配合物对癌细胞H460、HepG2、MCF7以及正常人体肝细胞HL7702的体外抑制活性;在Tris-HCl缓冲溶液中,以EB作为荧光探针,用荧光光谱法初步研究了配合物与小牛胸腺DNA的相互作用。结果表明:配合物C1、C2对3种癌细胞都有较好的抑制作用,配合物C2对HL7702的细胞毒性远小于C1;配合物C1、C2与小牛胸腺DNA作用均是插入结合作用所致。     

2-羰基-3-苯基丙酸芳甲酰腙二(2,4-二氯苄基)锡配合物的合成、晶体结构及生物活性

二（2,4-二氯苄基）二氯化锡分别与2-羰基-3-苯基丙酸苯甲酰腙及2-羰基-3-苯基丙酸水杨酰腙反应,合成了2个取代苄基锡配合物（C1、C2）,通过元素分析、IR、¹H NMR、¹³C NMR、¹¹⁹Sn NMR、X射线单晶衍射以及热重分析等表征了配合物结构。测试了配合物对癌细胞Hela、MCF7、HepG2、Colo205、NCI-H460以及正常人体胚肾细胞HEK293、正常人体肝细胞HL7702的体外抑制活性;在Tris-HCl缓冲溶液中,以EB做为荧光探针,用荧光光谱法初步研究了配合物与小牛胸腺DNA的相互作用。结果表明：配合物C1、C2对5种癌细胞都有明显的抑制作用,配合物C2对HEK293、HL7702的细胞毒性远小于C1;配合物C1与小牛胸腺DNA作用是插入结合与静电结合共同作用所致,配合物C2与小牛胸腺DNA作用是插入结合作用所致。     

N-(2-丙酸)-芳甲酰腙二对甲基苄基锡配合物的合成、晶体结构及生物活性

二对甲基苄基二氯化锡分别与N-（2-丙酸）-对硝基苯甲酰腙及N-（2-丙酸）-对叔丁基苯甲酰腙反应,合成了2个取代二苄基锡配合物（C1、C2）,通过元素分析、IR、UV-Vis、¹H NMR、¹³C NMR、¹¹⁹Sn NMR、X射线单晶衍射以及热重分析等表征了配合物结构。测试了配合物对癌细胞H460、HepG2、MCF7以及正常人体肝细胞HL7702的体外抑制活性;在Tris-HCl缓冲溶液中,以EB作为荧光探针,用荧光光谱法初步研究了配合物与小牛胸腺DNA的相互作用。结果表明：配合物C1、C2对3种癌细胞都有较好的抑制作用,配合物C2对HL7702的细胞毒性远小于C1;配合物C1、C2与小牛胸腺DNA作用均是插入结合作用所致。     

2-羰基丙酸芳甲酰腙二对甲基苄基锡配合物的合成、晶体结构及生物活性

在含水甲苯中,对甲基氯苄与锡粉反应合成了二对甲基苄基二氯化锡,将其分别与2-羰基丙酸苯甲酰腙及2-羰基丙酸水杨酰腙反应,合成了2个取代苄基锡配合物（1、2）,通过元素分析、IR、¹H NMR、¹³C NMR、X射线单晶衍射以及热重分析等表征了配合物结构。测试了配合物对癌细胞MCF-7、HepG2、NCI-H460以及正常人体肝细胞HL-7702的体外抑制活性;在Tris-HCl缓冲溶液中,以EB作为荧光探针,用荧光光谱法初步研究了配合物与小牛胸腺DNA的相互作用。结果表明：配合物1、2对3种癌细胞都有明显的抑制作用,配合物2对HL-7702的细胞毒性小于1;配合物1与小牛胸腺DNA作用是插入结合与静电结合共同作用所致,配合物2与小牛胸腺DNA作用是插入结合作用所致。     

微波辅助自组装合成有机锡配合物及其生物活性

利用微波"一锅法"合成了4个有机锡配合物(C1～C4),通过红外光谱(IR)、紫外可见吸收光谱(VisUV)、~1H NMR、~(13)C NMR、~(119)Sn NMR、高分辨率质谱(HRMS)、X射线单晶衍射以及热重分析等表征了配合物的结构.结构分析表明,配合物C1～C4均为中心对称的平面Sn_2O_2四元环结构.通过MTT法,测试了配合物C1～C4对癌细胞NCI-H460、HepG2、MCF7以及正常人体肝细胞HL7702的体外抑制活性,结果显示,配合物C1对3种癌细胞的抑制活性优于其他配合物及卡铂,有望成为金属有机抗癌药物候选化合物.通过紫外光谱、荧光光谱、黏度、分子对接实验,证实了配合物C1与DNA的相互作用是插入结合方式.     

氨·环己胺·羧酸根合铂(Ⅱ)类配合物的合成、抗肿瘤活性和与DNA的键合水平

本工作设计合成了6种新型氨·环己胺·羧酸根合铂!类配合物[Pt(NH3)(NH2)X2](a￣f)｛其中,X=CH3COO-(乙酸根),CH2ClCOO-(氯乙酸根),C6H5-COO-(苯甲酸根),p-CH3O-C6H4-COO-(对甲氧基苯甲酸根),p-CH3-C6H4-COO-(对甲基苯甲酸根),p-NO2-C6H4-COO-(对硝基苯甲酸根)｝。通过元素分析、摩尔电导、红外光谱、紫外光谱和1H核磁共振谱对配合物进行了表征。通过MTT法研究了配合物的体外抗肿瘤活性,通过流式细胞仪以及等离子体质谱研究了配合物对细胞周期的影响以及与细胞DNA的键合量;体外抗肿瘤活性测试表明,配合物(c￣f)对EJ和HL-602种肿瘤细胞表现出好的活性,而且配合物(c),(d)和(e)对EJ和HL-602种肿瘤细胞的活性高于临床用药顺铂;配合物(a￣f)对MCF-7、HCT-8和BGC-8233种肿瘤细胞的活性低于顺铂;它们能阻止HL-60和EJ细胞G2 M→G1期的进行;配合物(a￣f)与HL-60和EJ细胞的DNA键合量从大到小的顺序为:c>d>e>cisplatin>f>a>b。     

人血清白蛋白与Cu(II)配合物的生物活性研究

Cu(II)配合物很有可能成为下一代的抗肿瘤药物。本文以2-氨基-5-氯苯酚和2-喹啉甲醛合成的席夫碱作为配体,与Cu(II)络合形成配合物1。分别对配合物1和其与人血清白蛋白(HSA)的复合物HSA-1进行体外抗肿瘤测试,发现HSA能提高配合物1的抗肿瘤活性,并降低了对正常细胞的毒性。通过线粒体膜电位等实验,可以推断出配合物1是通过线粒体通路诱导癌细胞凋亡。     

去氢枞酸硝酸酯类化合物的合成及细胞毒性评价（英文）

为寻找高效的抗肿瘤活性化合物,设计并合成了一系列新型的去氢枞酸硝酸酯类化合物.采用噻唑蓝(MTT)法测定目标化合物对鼻咽癌(CNE-2)、肝癌(HepG2, BEL-7402)和宫颈癌(He La)细胞株以及人正常肝细胞株(HL-7702)和鼻咽上皮细胞株(NP69)的细胞毒活性.结果表明,大多数杂合物的细胞毒性明显高于母体化合物.其中,12-溴去氢枞酸-3'-硝氧基丙酯(5j)对鼻咽癌CNE-2细胞株的抑制增殖活性优于顺铂,IC50值为(8.36±0.14)μmol/L, 12,14-二硝基去氢枞酸-3'-硝氧基丙酯(5n)对肝癌BEL-7402细胞株的IC50值为(11.23±0.21)μmol/L.同时,目标化合物对人正常肝细胞株(HL-7702)和鼻咽上皮细胞株(NP69)表现出较低的细胞毒性.此外,对所有硝酸酯的NO释放量的测试表明,在大多数情况下,细胞毒性与CNE-2细胞株细胞内NO的释放水平呈正相关.     

Design,Synthesis and Pharmacological Evaluation of Three Novel Dehydroabietyl Piperazine Dithiocarbamate Ruthenium (II) Polypyridyl Complexes as Potential Antitumor Agents: DNA Damage,Cell Cycle Arrest and Apoptosis Induction

The use of cisplatin is severely limited by its toxic side-effects, which has spurred chemists to employ different strategies in the development of new metal-based anticancer agents. Here, three novel dehydroabietyl piperazine dithiocarbamate ruthenium (II) polypyridyl complexes (6a–6c) were synthesized as antitumor agents. Compounds 6a and 6c exhibited better in vitro antiproliferative activity against seven tumor cell lines than cisplatin, they displayed no evident resistance in the cisplatin-resistant cell line A549/DPP. Importantly, 6a effectively inhibited tumor growth in the T-24 xenograft mouse model in comparison with cisplatin. Gel electrophoresis assay indicated that DNA was the potential targets of 6a and 6c, and the upregulation of p-H2AX confirmed this result. Cell cycle arrest studies demonstrated that 6a and 6c arrested the cell cycle at G1 phase, accompanied by the upregulation of the expression levels of the antioncogene p27 and the down-regulation of the expression levels of cyclin E. In addition, 6a and 6c caused the apoptosis of tumor cells along with the upregulation of the expression of Bax, caspase-9, cytochrome c, intracellular Ca²⁺ release, reactive oxygen species (ROS) generation and the downregulation of Bcl-2. These mechanistic study results suggested that 6a and 6c exerted their antitumor activity by inducing DNA damage, and consequently causing G1 stage arrest and the induction of apoptosis.     

Cytotoxic and apoptotic activities of novel Pd(II) complexes against human leukemia cell lines in vitro

In the investigation for alternative chemotherapeutic strategies against leukemia, Pd(II) complexes were synthesized and investigated for cytotoxic and apoptotic properties on two human leukemia cell lines (HL-60 and K562). Pd(II) complexes (Pd-5a and Pd-6a) with 5a and 6a as ligands were synthesized and characterized by ¹H-NMR and F-TIR. The cytotoxicity of the compounds was quantified using MTT method. Bax, Bcl-2, and caspase 3 gene expression levels were estimated using RT-qPCR. Here we show that Pd(II) complexes have important cytotoxic activity on human leukemia cell lines. RT-qPCR indicated that Bax and caspase 3 gene expression levels were increased after 24 h treatment with Pd-5a and Pd-6a complexes in both HL-60 and K562 cells at some selected dose. Furthermore, Bcl-2 gene expression level decreased after 24 h treatment with Pd-5a and Pd-6a complexes in K562 cells at all selected dose. In HL-60 cells, only one selected Pd-5a dose (25 µM) decreased the gene expression level of Bcl-2. The results obtained in the present investigation indicate that these two newly synthesized Pd(II) complexes have apoptotic effects at appropriate doses through caspase 3 and Bax genes and might represent a novel potentially active agents for the management of human leukemia cell lines.     

Design,syntheses and antitumor activities evaluation of 1,5-diaryl substituted pyrazole secnidazole ester derivatives

According to the drug hybridization principle, a series of novel 1,5-diaryl substituted pyrazole secnidazole ester derivatives ( 6aa – 6gc ) have been synthesized by the combinations of various 1,5-diarylpyrazole-3-carboxylic acids with secnidazole. The in vitro antitumor/cytotoxicities activities against tumor and normal cell lines, including NCI-H460 (lung tumor cell), MCG-803 (gastric tumor cell), Skov-3 (ovarian tumor cell), BEL-7404 (liver tumor cell) and HL-7702 (normal liver cell), have been evaluated using MTT assay. All compounds showed promising inhibitory activities against four tumor cell lines. The IC₅₀ of 6bc against the BEL-7404 cell was 2.03 μM, and those of 6fc against the NCI-H460, MCG-803 and Skov-3 were 1.34, 0.14, and 0.87 μM, respectively. All these values were much lower than those of the cisplatin. Furthermore, 6fc and 6bc were also verified to be considerably safe for normal human liver cell, since the lower IC₅₀ values than cisplatin. Based on these results, the cell cycle analysis, apoptosis ratio detection and mitochondrial membrane potential assay of 6fc and 6bc were further performed aiming to investigate their inhibition mechanism of BEL-7404 cells. It is revealed that they have effectively inhibited the cell growth by arresting the BEL-7404 cells at S phase and induced apoptosis through the mitochondria-mediated pathway.     

Synthesis,Characterization, DNA/HSA Interactions,and Anticancer Activity of Two Novel Copper(II) Complexes with 4-Chloro-3-Nitrobenzoic Acid Ligand

The purpose of this study was to identify new metal-based anticancer drugs; to this end, we synthesized two new copper(II) complexes, namely [Cu(ncba)₄(phen)] (1) and [Cu(ncba)₄(bpy)] (2), comprised 4-chloro-3-nitrobenzoic acid as the main ligand. The single-crystal XRD approach was employed to determine the copper(II) complex structures. Binding between these complexes and calf thymus DNA (CT-DNA) and human serum albumin (HSA) was explored by electronic absorption, fluorescence spectroscopy, and viscometry. Both complexes intercalatively bound CT-DNA and statically and spontaneously quenched DNA/HSA fluorescence. A CCK-8 assay revealed that complex 1 and complex 2 had substantial antiproliferative influences against human cancer cell lines. Moreover, complex 1 had greater antitumor efficacy than the positive control cisplatin. Flow cytometry assessment of the cell cycle demonstrated that these complexes arrested the HepG2 cell cycle and caused the accumulation of G0/G1-phase cells. The mechanism of cell death was elucidated by flow cytometry-based apoptosis assays. Western blotting revealed that both copper(II) complexes induced apoptosis by regulating the expression of the Bcl-2(Bcl-2, B cell lymphoma 2) protein family.     

Platinum(II) complexes of reduced amino acid ester Schiff bases: synthesis, characterization, and antitumor activity

A series of platinum(II) complexes of reduced amino acid esters Schiff bases were synthesized as potential anticancer agents and characterized by ¹H NMR, EA, IR, and molar conductivity. These compounds were tested for their DNA interaction with salmon sperm DNA by ultraviolet spectrum and CD spectrum, and their in vitro anticancer activities have been validated against HL-60, KB, BGC-823, and Bel-7402 cell lines by MTT assay. The cytotoxicity of complexes 5d and 5f are better than cisplatin against Bel-7402 cell lines, and show a close cytotoxic effect against HL-60 cell line.     

Crystal Structures,Cytotoxicity, Cell Apoptosis Mechanism,and DNA Binding of Two 8-Hydroxylquinoline Zinc(II) Complexes

Two zinc(II) complexes, [Zn₄(HOQ)₆Ac₂] (I) (HOQ = 8-hydroxylquinoline) and [Zn₄(MeQ)₆Ac₂] (II) (MeQ = 2-methyl-8-hydroxylquinoline), were synthesized and characterized by IR spectroscopy, ESI-MS spectrometry, elemental analysis and single crystal X-ray diffraction analysis (CIF files CCDC nos. 1433544 (I) and 1433546 (II)). The in vitro cytotoxicity of the two complexes, which was first reported, was evaluated by MTT assay against a series of tumor cell lines as well as HL-7702 normal liver cell line. The results indicated that they showed significantly higher cytotoxicity than cispltain on BEL-7404 cells with IC₅₀ values of 11.85 ± 0.06 μM (I) and 8.40 ± 0.07 μM (II), respectively. Further apoptosis mechanism studies on BEL-7404 cells suggested that their antitumor activities were achieved through cell apoptosis and arrest at G1 or S phase. The decline of mitochondrial membrane potential, the elevation of reactive oxygen species and cytoplasmic calcium concentration ([Ca²⁺]_c), the raise of caspase-3/9 activity indicated that complexes I and II induced apoptosis of BEL-7404 by a mitochondrial dysfunction pathway. Investigations on the binding properties of complexes I and II to ct-DNA by UV-Vis, circular dichroism spectra and agarose gel electrophoresis indicated that the two complexes could bind with ct-DNA via an intercalative mode.     

Water‐soluble Schiff base Cu(II) and Zn(II) complexes: Synthesis,DNA targeting ability and chemotherapeutic potential of Cu(II) complex for hepatocellular carcinoma – in vitro and in vivo approach

Reliable compounds with low toxicity are tempting potential chemotherapeutics. With an aim of achieving less toxic but more potent metallodrugs, four new‐generation hydrophilic Cu(II) and Zn(II) complexes with DNA‐targeting properties were synthesized and characterized using various physicochemical data. The excellent DNA binding and cleavage results confirmed the mode of binding of DNA with the complexes and their ability to denature it. The profound in vitro cytotoxicity exhibited by complex 3 against a panel of cell lines (HeLa, MCF‐7 and HepG‐2) along with NHDF (normal human dermal fibroblasts) with distinct activity towards HepG‐2 and low toxicity to NHDF prompted in vivo studies of induced hepatocellular carcinoma‐affected Swiss albino rats. On evaluating various serum hepatic, biological and histopathological parameters, complex 3 showed excellent activity in restoring the damaged liver to normal. As a means of identifying the pathway of DNA damage, flow cytometric evaluation of cell cycle analysis was performed, which revealed S phase arrest‐induced apoptosis in HepG‐2 cells by complex 3 , making it a cell cycle‐specific drug.